Format

Send to

Choose Destination
J Hematol Oncol. 2013 Sep 30;6(1):74. doi: 10.1186/1756-8722-6-74.

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Author information

1
Institute of Hematology, Jinan University, Guangzhou 510632, China. yangqiuli@hotmail.com.

Abstract

T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. We are beginning to understand the power of co-inhibitors in the context of lymphocyte homeostasis and the pathogenesis of leukemia, which involves several newly described co-inhibitory pathways, including the programmed death-1 (PD-1) and PD-1 ligand (PD-L1) pathway. The aim of this review is to summarize the PD-1 and PD-L1 biological functions and their alterative expression in hematological malignancies. The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed.

PMID:
24283718
PMCID:
PMC3851976
DOI:
10.1186/1756-8722-6-74
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center